SYNERGICE MAKE MORE POSSIBLE
Live / Applied — First extension granted (statement of use) (as of 28 Jan 2026)
What this means for you
Not registered yet, but its 31 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98830251
- Mark type
- Slogan / phrase
- Filed
- 31 Oct 2024
- Published for opposition
- 03 Jun 2025
- Attorney of record
- Zach Gordon
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for treatment of Musculo skeletal pain; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of Psychiatric disorders; pharmaceutical preparations for treatment of human immunodeficiency virus (HIV); pharmaceutical preparations for treatment Gastro Intestinal illnesses and disorders; pharmaceutical preparations for treatment of allergies; pharmaceutical preparations for treatment of viral illnesses; pharmaceutical preparations for treatment of bacterial illnesses; pharmaceutical preparations for diabetes management; pharmaceutical preparations for treatment of gout; pharmaceutical preparations for treatment of fungal infections; pharmaceutical preparations for treatment of attention deficit disorder; pharmaceutical preparations for treatment of immune disorders; pharmaceutical preparations for treatment of neurological disorders and neurological illness; pharmaceutical preparations for treatment of cardiovascular illnesses; pharmaceutical preparations for treatment of urological issues; pharmaceutical preparations for treatment of sleep disorders; pharmaceutical preparations for treatment of sexual disorders; pharmaceutical preparations for bronchodilation; pharmaceutical preparations for treatment of thyroid disorders; pharmaceutical preparations for treatment of hormonal disorders; Tablet preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; gelatin capsule preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; powder preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; syrup preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; cream preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; oral solution preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes
- Class 035 — Advertising and business services: Business to business services in the nature of generating business leads, business development, providing business information, and business intermediary services in the nature of acting as single point of contact between clients and vendors, all in the field of generic pharmaceuticals
Owner
- Strides Pharma Science Limited, Bangalore, IN
- Strides Pharma Science Limited, Bangalore, IN
Prosecution history
- 19 Aug 2026 — TEAS STATEMENT OF USE RECEIVED
- 29 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2026 — SOU EXTENSION 1 GRANTED
- 28 Jan 2026 — SOU EXTENSION 1 FILED
- 28 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 30 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Jun 2025 — PUBLISHED FOR OPPOSITION
- 28 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 May 2025 — EXAMINER'S AMENDMENT ENTERED
- 01 May 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 01 May 2025 — EXAMINERS AMENDMENT E-MAILED
- 01 May 2025 — EXAMINERS AMENDMENT -WRITTEN
- 01 May 2025 — ASSIGNED TO EXAMINER